When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Diabetes medication - Wikipedia

   en.wikipedia.org/wiki/Diabetes_medication

   Type 2 diabetes is the most common type of diabetes. Treatments include agents that (1) increase the amount of insulin secreted by the pancreas, (2) increase the sensitivity of target organs to insulin, (3) decrease the rate at which glucose is absorbed from the gastrointestinal tract, and (4) increase the loss of glucose through urination.

3. Dulaglutide - Wikipedia

   en.wikipedia.org/wiki/Dulaglutide

   Dulaglutide, sold under the brand name Trulicity among others, [8] is a medication used for the treatment of type 2 diabetes in combination with diet and exercise. [9] [10] It is also approved in the United States for the reduction of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.

4. Meglitinide - Wikipedia

   en.wikipedia.org/wiki/Meglitinide

   A 2020 Cochrane systematic review did not find enough evidence of reduction of all-cause mortality, serious adverse events, cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke or end-stage renal disease when comparing metformin monotherapy to meglitinide for the treatment of type 2 diabetes.

5. Teplizumab - Wikipedia

   en.wikipedia.org/wiki/Teplizumab

   Teplizumab, sold under the brand name Tzield, is a humanized anti-CD3 monoclonal antibody that is the first approved treatment indicated to delay the onset of stage 3 type 1 diabetes in people with stage 2 type 1 diabetes. [3] [4] [5] The Fc region of this antibody has been engineered to have Fc receptor non-binding (FNB) properties. [6]

6. A New Study Tentatively Links Drugs Like Ozempic To Sudden ...

   www.aol.com/study-tentatively-links-drugs...

   The injectable drug, which is sold under the brand names Wegovy and Ozempic, is FDA-approved to help with weight loss and type 2 diabetes, but research and general use by the public has turned up ...

7. SGLT2 inhibitor - Wikipedia

   en.wikipedia.org/wiki/SGLT2_inhibitor

   Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors ...